Targeting of Myc transcription and CD44v6 with dinaciclib and taselisib, respectively, significantly affected the growth of tumor xenografts generated by subcutaneous injection of aggressive KRAS-mutant/MYC-amplified CR-CSphCs, without affecting mice weight (Figure 4I and Figure S4F). This evidence concerns the gene KRAS and neoplasm.